Myeloproliferative neoplasm future or investigational therapies

Jump to navigation Jump to search

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm future or investigational therapies

on Myeloproliferative neoplasm future or investigational therapies

Myeloproliferative neoplasm future or investigational therapies in the news

Blogs on Myeloproliferative neoplasm future or investigational therapies

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Future or investigational therapies in myeloproliferative neoplasms include BLU-285, JQ1, and suberoyl anilide hydroxamic acid. Each of these investigational agents carries a unique mechanism of action on myeloid cells. The agents are currently in clinical trials.

Future or investigational therapies

  • BLU-285: This medication is a selective KIT D816V inhibitor that is currently in clinical trials in mastocytosis.[1] The preliminary data presented at the American Society of Hematology meeting in 2017 showed promising results. It is generally well-tolerated. BLU-285 remains in clinical trials.
  • JQ1: This medication is a bromodomain-containing protein 4 (BRD4) inhibitor that is currently being studies in advanced mastocytosis. JQ1 works by blocking the interaction between BRD4 and acetylated histones. It functions as an epigenetic modifying agent, since it influences histone activity and thereby regulates gene transcription. JQ1 triggers apoptosis in cells.[1]

References

  1. 1.0 1.1 1.2 Vaes M, Benghiat FS, Hermine O (2017). "Targeted Treatment Options in Mastocytosis". Front Med (Lausanne). 4: 110. doi:10.3389/fmed.2017.00110. PMC 5517467. PMID 28775983.

Template:WH Template:WS